CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (87,053)	$ (65,153)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	103	86
Amortization of deferred financing costs	4,060
Stock-based compensation expense	7,724	3,187
Value of common stock issued for patent license	71
Accretion of discount/premium on available for sale securities	(97)	28
Change in fair value of derivative instruments-warrants	364	(1,404)
Changes in operating assets and liabilities:
Security deposit	(56)	(69)
Accounts payable and accrued expenses	(1,042)	3,086
Prepaid expenses and other current assets	2,781	(394)
Accrued interest expense on Senior Convertible Debentures	2,470
Total Adjustments	16,378	4,520
Net Cash used in Operating Activities	(70,675)	(60,633)
Cash Flows From Investing Activities:
Net purchases of available-for-sale securities	(50,188)	30,000
Additions to property and equipment	(50)	(104)
Repayment on ContraVir loan receivable		455
Net Cash (used in) / provided by Investing Activities	(50,238)	30,351
Cash Flows From Financing Activities:
Proceeds of sale of common stock	14,672	25,612
Proceeds of sale of common stock - ContraVir		3,224
Fees and expenses - sale of common stock	(404)	(721)
Proceeds from exercise of warrants	1,012
Proceeds from exercise of stock options	1,079	36
Distribution associated with ContraVir Spinoff		(3,230)
Net Cash provided by Financing Activities	16,359	24,921
Net decrease in cash and cash equivalents	(104,554)	(5,361)
Cash and cash equivalents at beginning of period	146,470	18,130
Cash and cash equivalents at end of period	41,916	12,769
Supplementary disclosure of cash flow information:
Cash paid for interest on Senior Convertible Debentures	7,416
Cash paid for taxes	258	55
Supplementary disclosure of non-cash investing and financing activities:
Distribution of net assets of ContraVir		$ 84
Conversion of Senior Convertible Debentures to Synergy Common Stock	$ 40,989